The latest price target for HCW Biologics (NASDAQ:HCWB) was reported by EF Hutton on June 1, 2023. The analyst firm set a price target for $9.00 expecting HCWB to rise to within 12 months (a possible 2761.69% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for HCW Biologics (NASDAQ:HCWB) was provided by EF Hutton, and HCW Biologics their buy rating.

There is no last upgrade for HCW Biologics

There is no last downgrade for HCW Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HCW Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HCW Biologics was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.

While ratings are subjective and will change, the latest HCW Biologics (HCWB) rating was a with a price target of $0.00 to $9.00. The current price HCW Biologics (HCWB) is trading at is $0.31, which is within the analyst’s predicted range.